[The synthetic peptide preparation dalargin in the treatment of peptic ulcer].

Abstract

The paper is concerned with the results of clinical assessment of a new peptide drug dalargin in therapy of duodenal peptic ulcer. Assessment of the efficacy of dalargin was compared to that of tagamet and placebo using double "blind" control. A total of 180 males with exacerbation of duodenal ulcer were examined, of them 90 received dalargin only, 70 received tagamet and 20 persons participated in an experiment based on a method of double "blind" control. An average period of duodenal ulcer healing in the patients on dalargin therapy was 21.4 +/- 1.2 days, and by the 28th day complete cicatrization was observed in 87.5% of the patients. In tagamet therapy an average period of cicatrization was 23.7 +/- 1.8 days, by the 28th day ulcer healing was observed in 87.3%. With placebo ulcer healing by the 4th week was observed in 30% of the examinees, in dalargin therapy in 80%. A conclusion was made of high efficacy of dalargin for therapy of peptic ulcer.

• Authors: V G Smagin, V A Vinogradov, S A Bulgakov, E P Propisnova, M I Titov
• Journal: Terapevticheskii arkhiv (Ter Arkh) Vol. 59 Issue 2 Pg. 44-8 ( 1987) ISSN: 0040-3660 [Print] Russia (Federation)
• Vernacular Title: Sinteticheskiĭ peptidnyĭ preparat dalargin v lechenii iazvennoĭ bolezni.
• PMID: 3554590 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• Enkephalin, Leucine
• Enkephalin, Leucine-2-Alanine
• Cimetidine
• enkephalin-Leu, Ala(2)-Arg(6)-

Topics

• Adolescent
• Adult
• Cimetidine (therapeutic use)
• Clinical Trials as Topic
• Double-Blind Method
• Duodenal Ulcer (drug therapy)
• Enkephalin, Leucine (analogs & derivatives, therapeutic use)
• Enkephalin, Leucine-2-Alanine (analogs & derivatives)
• Humans
• Male
• Middle Aged